Physician profile
Michael Antoine
NPI 1801363809
$712.56
in general payments reported to CMS, 2019-2025
15 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.19 · 2023: $159 · 2024: $122 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $107.60 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $105.22 | 2025 | Cobenfy |
| Abbvie INC. | $75.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $72.57 | 2023-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $61.93 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $46.36 | 2021-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $41.66 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.43 | 2025 | Caplyta |
| Bausch Health US, LLC | $34.02 | 2024 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $32.71 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $24.06 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $20.30 | 2023 | Auvelity |
| Alkermes, INC. | $18.30 | 2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $15.84 | 2023 | Xelstrym |
| Neos Therapeutics, LP | $14.77 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Antoine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.